Enovis Announces Fourth Quarter and Full Year 2023 Results
Wilmington, DE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- —Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2023.
- Wilmington, DE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- —Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2023.
- Enovis’ fourth-quarter net sales of $455 million grew 11% from the same quarter in 2022, including 8% organic growth.
- Fourth quarter results reflect continued execution in P&R, above-market growth in Recon, and the impact of recent acquisitions.
- Enovis’ full year 2023 net sales of $1.7 billion grew 9% year over year, including 8% organic growth.